Clinical Practice Surveillance of the Use of Herceptin® Subcutaneous in Patients With HER2-Positive Early Breast Cancer (HerSCin)

Trial Profile

Clinical Practice Surveillance of the Use of Herceptin® Subcutaneous in Patients With HER2-Positive Early Breast Cancer (HerSCin)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms HerSCin
  • Sponsors Roche
  • Most Recent Events

    • 24 Apr 2017 Planned End Date changed from 1 Jul 2016 to 1 Jul 2018.
    • 24 Apr 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2018.
    • 07 Jun 2016 Interim results (n = 130) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top